Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Supratek Pharma Inc.
DescriptionAnti-metastatic compound, S100A4 inhibitor
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat metastatic cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today